Literature DB >> 15696961

Protocol of radiotherapy for glioblastoma according to the expression of HIF-1.

Nobuyuki Irie1, Takayuki Matsuo, Izumi Nagata.   

Abstract

Hypoxia is a common feature of many malignant neoplasms and has been identified as a major reason for the radioresistance of malignant tumor tissue. On the other hand, the transcription factor hypoxia-inducible factor-1 (HIF-1) has attracted attention because it is rapidly expressed when tissue oxygen tension is reduced, thus playing the role of a hypoxic sensor. We investigated whether the level of HIF-1 expression in glioblastoma (GBM) could be an indicator in a protocol for postoperative radiotherapy. We immunohistologically evaluated the level of HIF-1 expression in 60 pathologically diagnosed GBMs. HIF-1 expression was positive in all tumors. The progression-free survival of the group receiving only conventional radiotherapy after surgery differed significantly according to the level of HIF-1 expression. The results of this study suggest that the HIF-1 expression level can be an indicator of tumor radioresistance, and that prior knowledge of the HIF-1 expression level allows the formulation of a protocol for postoperative radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15696961     DOI: 10.1007/bf02482169

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  14 in total

1.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

2.  Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image.

Authors:  Ryota Mashiko; Shingo Takano; Eiichi Ishikawa; Tetsuya Yamamoto; Kei Nakai; Akira Matsumura
Journal:  J Neurooncol       Date:  2010-07-02       Impact factor: 4.130

3.  Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.

Authors:  K Tateishi; U Tateishi; M Sato; S Yamanaka; H Kanno; H Murata; T Inoue; N Kawahara
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

4.  Hyaluronan regulates ceruloplasmin production by gliomas and their treatment-resistant multipotent progenitors.

Authors:  Sandra L Tye; Anne G Gilg; Lauren B Tolliver; William G Wheeler; Bryan P Toole; Bernard L Maria
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 5.  Exploiting metabolic differences in glioma therapy.

Authors:  Francesca Galeffi; Dennis A Turner
Journal:  Curr Drug Discov Technol       Date:  2012-12

6.  Hypoxia-related molecules HIF-1α, CA9, and osteopontin : predictors of survival in patients with high-grade glioma.

Authors:  O P Erpolat; P U Gocun; M Akmansu; G Ozgun; G Akyol
Journal:  Strahlenther Onkol       Date:  2012-12-22       Impact factor: 3.621

7.  Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin.

Authors:  Tie Fu Liu; Jiaozhong Cai; Denise M Gibo; Waldemar Debinski
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

Review 8.  The role of hypoxia-inducible factors in tumorigenesis.

Authors:  E B Rankin; A J Giaccia
Journal:  Cell Death Differ       Date:  2008-02-15       Impact factor: 15.828

Review 9.  Microenvironment and radiation therapy.

Authors:  Michio Yoshimura; Satoshi Itasaka; Hiroshi Harada; Masahiro Hiraoka
Journal:  Biomed Res Int       Date:  2012-12-04       Impact factor: 3.411

Review 10.  Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors.

Authors:  Chan Joo Yeom; Yoko Goto; Yuxi Zhu; Masahiro Hiraoka; Hiroshi Harada
Journal:  Int J Mol Sci       Date:  2012-10-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.